NASDAQ:HSIC - Nasdaq - US8064071025 - Common Stock - Currency: USD
Although the revenue and EPS for Henry Schein (HSIC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Dental and medical products company Henry Schein (NASDAQ:HSIC) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $3.17 billion. Its non-GAAP profit of $1.15 per share was 3.6% above analysts’ consensus estimates.
Dental and medical products company Henry Schein (NASDAQ:HSIC) will be announcing earnings results tomorrow before the bell. Here’s what investors should know.
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: MCK
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CAH
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: WST
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQ:HSIC) and the best and worst performers in the dental equipment & technology industry.